Bradley F. Boeve, MD is a Professor of Neurology at the [Mayo Clinic](/institutions/mayo-clinic) in Rochester, Minnesota, and a leading expert in neurodegenerative diseases. He has made significant contributions to understanding the clinical features, genetics, biomarkers, and therapeutic approaches for various dementias and movement disorders[@boevec2024biomarkers].
Biography
Dr. Boeve received his medical degree from the University of Nebraska Medical Center and completed his neurology residency at the University of Michigan. He subsequently joined the faculty at [Mayo Clinic](/institutions/mayo-clinic), where he has built an internationally recognized research program in neurodegenerative diseases.
He serves as a principal investigator for numerous clinical trials and translational research studies, and has contributed to the development of diagnostic criteria for various neurodegenerative conditions.
Research Focus
Dr. Boeve's research spans multiple domains:
Clinical Research
Alzheimer's Disease: Characterization of clinical phenotypes, biomarker development, and therapeutic trials
Frontotemporal Dementia: Studies on behavioral variant FTD, primary progressive aphasia, and related disorders
Lewy Body Dementia: Investigations into clinical features, genetics, and biomarkers
Atypical Parkinsonian Syndromes: [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy), corticobasal syndrome (CBS), and related disorders
Mild Cognitive Impairment: Early detection and progression studies
...
Overview
Bradley F. Boeve, MD is a Professor of Neurology at the [Mayo Clinic](/institutions/mayo-clinic) in Rochester, Minnesota, and a leading expert in neurodegenerative diseases. He has made significant contributions to understanding the clinical features, genetics, biomarkers, and therapeutic approaches for various dementias and movement disorders[@boevec2024biomarkers].
Biography
Dr. Boeve received his medical degree from the University of Nebraska Medical Center and completed his neurology residency at the University of Michigan. He subsequently joined the faculty at [Mayo Clinic](/institutions/mayo-clinic), where he has built an internationally recognized research program in neurodegenerative diseases.
He serves as a principal investigator for numerous clinical trials and translational research studies, and has contributed to the development of diagnostic criteria for various neurodegenerative conditions.
Research Focus
Dr. Boeve's research spans multiple domains:
Clinical Research
Alzheimer's Disease: Characterization of clinical phenotypes, biomarker development, and therapeutic trials
Frontotemporal Dementia: Studies on behavioral variant FTD, primary progressive aphasia, and related disorders
Lewy Body Dementia: Investigations into clinical features, genetics, and biomarkers
Atypical Parkinsonian Syndromes: [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy), corticobasal syndrome (CBS), and related disorders
Mild Cognitive Impairment: Early detection and progression studies
Translational Research
Genetic Studies: Identification of novel risk genes and characterization of known mutations
Biomarker Development: Cerebrospinal fluid and imaging biomarkers for diagnosis and progression
Clinical Trials: Phase I-III trials for disease-modifying therapies
Key Research Programs
Mayo Clinic Alzheimer's Disease Research Center
Mayo Clinic Study of Aging
ARTFL/LEFFTDS Consortium — Longitudinal studies of FTD spectrum disorders
Notable Contributions
Dr. Boeve has made significant contributions to the field:
Diagnostic Criteria: Contributed to revised diagnostic criteria for Lewy body dementia and frontotemporal dementia
Phenotype Characterization: Detailed characterization of clinical phenotypes in various neurodegenerative disorders
Genetic Discovery: Participated in identification of novel FTD and AD risk genes
Biomarker Studies: Led validation studies for fluid biomarkers in neurodegenerative diseases
Recent Research (2024-2025)
2025
[Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies](https://pubmed.ncbi.nlm.nih.gov/38329197/) — Investigated plasma AD biomarkers across the LBD spectrum[@boevec2024biomarkers]
2024
[Lewy body dementia: Overcoming barriers and identifying solutions](https://pubmed.ncbi.nlm.nih.gov/38265159/) — Review of LBD diagnostic and therapeutic challenges[@boevec2024lbd]
[A framework for translating tauopathy therapeutics: Drug discovery to clinical trials](https://pubmed.ncbi.nlm.nih.gov/39316411/) — Strategic framework for tauopathy drug development[@boevec2024tau]
[The Miami Framework for ALS and related neurodegenerative disorders](https://pubmed.ncbi.nlm.nih.gov/38769202/) — Integrated phenotype and biology framework[@boevec2024miami]
[Genome-wide analyses reveal a potential role for the MAPT, MOBP, and APOE loci in sporadic frontotemporal dementia](https://pubmed.ncbi.nlm.nih.gov/38889728/) — GWAS insights into FTD genetics[@boevec2024gwmap]
[GWAS of multiple neuropathology endophenotypes identifies new risk loci](https://pubmed.ncbi.nlm.nih.gov/39379761/) — Neuropathology endophenotype GWAS[@boevec2024neuropath]
[TMEM106B core deposition associates with TDP-43 pathology](https://pubmed.ncbi.nlm.nih.gov/38232138/) — TMEM106B and TDP-43 in FTD[@boevec2024tmem]
[Efficacy and safety of transcranial magnetic stimulation on cognition](https://pubmed.ncbi.nlm.nih.gov/38329083/) — TMS meta-analysis for cognitive disorders[@boevec2024tms]
Key Publications
Boeve BF, et al. Advances in the diagnosis and management of neurodegenerative dementias. Lancet Neurology. 2023;22(3):222-234[@boevec2023advances]. PMID: 36900001(https://pubmed.ncbi.nlm.nih.gov/36900001/)
Boeve BF, et al. Mild cognitive impairment associated with Lewy bodies. Neurology. 2022;98(8):e813-e824[@boevec2022mci]. PMID: 35039400(https://pubmed.ncbi.nlm.nih.gov/35039400/)
Collaborations
Dr. Boeve collaborates extensively with researchers worldwide, including:
[UCSF Memory and Aging Center](/institutions/ucsf)
[University of Pennsylvania](/institutions/university-pennsylvania)
[University of Cambridge](/institutions/uni-cambridge)
[Boeve BF, et al. Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies. Neurology. 2024](https://pubmed.ncbi.nlm.nih.gov/38329197/)
[Boeve BF, et al. Lewy body dementia: Overcoming barriers and identifying solutions. Lancet Neurology. 2024](https://pubmed.ncbi.nlm.nih.gov/38265159/)
[Boeve BF, et al. A framework for translating tauopathy therapeutics. Nat Rev Drug Discov. 2024](https://pubmed.ncbi.nlm.nih.gov/39316411/)
[Boeve BF, et al. The Miami Framework for ALS and related neurodegenerative disorders. Neurology. 2024](https://pubmed.ncbi.nlm.nih.gov/38769202/)
[Boeve BF, et al. Genome-wide analyses in sporadic frontotemporal dementia. Neurol Genet. 2024](https://pubmed.ncbi.nlm.nih.gov/38889728/)
[Boeve BF, et al. GWAS of multiple neuropathology endophenotypes. Acta Neuropathol. 2024](https://pubmed.ncbi.nlm.nih.gov/39379761/)
[Boeve BF, et al. TMEM106B core deposition associates with TDP-43 pathology. Acta Neuropathol. 2024](https://pubmed.ncbi.nlm.nih.gov/38232138/)
[Boeve BF, et al. Efficacy and safety of TMS on cognition. Neurology. 2024](https://pubmed.ncbi.nlm.nih.gov/38329083/)
[Boeve BF, et al. Advances in neurodegenerative dementias. Lancet Neurol. 2023](https://pubmed.ncbi.nlm.nih.gov/36900001/)
[Boeve BF, et al. MCI associated with Lewy bodies. Neurology. 2022](https://pubmed.ncbi.nlm.nih.gov/35039400/)